Nathan Farley, MD
Retina Specialist · Traverse City, MINPI 1427476035
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Genentech USA, Inc. at 31.4% of the total. Reporting peaked in 2020 at $4,987 and has fallen 81.7% since, to $911 in 2025.
Across 127 payments — averaging $96.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$4K
- Alimera Sciences, Inc.$4K
- Novartis$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Regeneron$921
- ANI Pharmaceuticals, Inc.$270
- plus $824 from 8 others
Across 32 payments — averaging $5016.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Apellis Pharmaceuticals, Inc.$161K
What the payments were for
- Consulting fees$4,35336%
- Speaking & faculty fees$3503%
- Travel & lodging$8847%
- Food & beverage$6,59854%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 16 | $3,836 |
| Alimera Sciences, Inc. | 20 | $3,674 |
| Novartis | 10 | $1,453 |
| Regeneron Healthcare Solutions, Inc. | 32 | $1,223 |
| Regeneron | 3 | $921 |
| ANI Pharmaceuticals, Inc. | 9 | $270 |
| Apellis Pharmaceuticals, Inc. | 10 | $235 |
| AbbVie(2 entities) | 7 | $171 |
| Astellas Pharma US Inc | 6 | $136 |
| Bausch & Lomb Americas Inc. | 5 | $102 |
| Eyepoint US, Inc. | 5 | $78 |
| Alcon | 1 | $55 |
| Biogen | 2 | $38 |
| Oculus Surgical Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,200 in reported general payments places this provider in the 70th percentile of 52 retina specialist providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 287 | $13,993 |
| Difluprednate | 49 | $4,796 |
| Ketorolac Tromethamine | 123 | $2,837 |
| Brinzolamide | 11 | $1,628 |
| Dorzolamide Hcl | 47 | $1,034 |
| Timolol Maleate | 81 | $1,008 |
| Gentamicin Sulfate | 75 | $744 |
| Acetazolamide ErAcetazolamide | 20 | $724 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 26 | $699 |
| Brimonidine Tartrate | 43 | $422 |
| Prednisone | 32 | $233 |
| Latanoprost | 12 | $141 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Traverse City
- Douglas CovertTraverse City$6K
- Scott SneedTraverse City$4K
- Diane FianderTraverse City$3K
- Kean OhTraverse City$1K
- Jeremy WolfeRoyal Oak$809K
- Lisa FaiaRoyal Oak$520K
- Tarek HassanRoyal Oak$460K
- Asheesh TewariDearborn$204K
- Sandeep RandhawaRoyal Oak$94K
- Kimberly DrenserRoyal Oak$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.